CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
虚弱并非失败：合并症对接受 CAR-T 治疗的 LBCL 患者非复发死亡率与安全性的影响有限
英文原题：Frail is not fail: Limited impact of comorbidities on non-relapse mortality and safety in patients with LBCL treated with CAR-T.
查看英文原题
Frail is not fail: Limited impact of comorbidities on non-relapse mortality and safety in patients with LBCL treated with CAR-T.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
我们将三种主要的合并症评分系统——CIRS、HCT-CI和Severe4——应用于379例接受CAR-T 治疗的LBCL患者队列。根据所使用的评分，7%至34%的患者被确定为高合并症负担。然而，高合并症负担并未对CAR-T 治疗的耐受性产生负面影响，包括CRS的发生率或血液学毒性。低合并症负担与高合并症负担患者之间，tocilizumab和皮质类固醇的使用情况相当，非复发死亡率的累积发生率也相当。
展开英文摘要原文
We applied three major comorbidity scoring systems-CIRS, HCT-CI, and Severe4-to a cohort of 379 patients with LBCL treated with CAR-T therapy. A high comorbidity burden was identified in 7% to 34% of patients, depending on the score used.
However, a high comorbidity burden did not negatively impact the tolerability of CAR-T treatment, including the incidence of CRS, or hematologic toxicity. The use of tocilizumab and corticosteroids was comparable between patients with low and high comorbidity burden, as was the cumulative incidence of non-relapse mortality.
论文信息
- 作者
- Galli E、Di Blasi R、Pansini I、Cristinelli C、Bommier C、De Bernardis I、Corrente A、Viscovo M
- 单位
- Department of Laboratory and Hematological Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.Italy
- 期刊
- British journal of haematology2025 Jun 23
- 原文标识
- PubMed 40551480 · DOI 10.1111/bjh.20222
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →